盤中異動 | 復星醫藥盤中上漲10%,報於33.0港元
2022年5月11日9時43分,復星醫藥(HK02196)盤中上漲10%,報於33.0港元,成交額達9778.21萬港元,換手率達到0.06%。
4月28日訊,4月28日復星醫藥(02196.HK)公佈,近日,公司控股子公司上海復宏漢霖生物醫藥有限公司(以下簡稱"漢霖醫藥",亦繫上海復宏漢霖生物技術股份有限公司的控股子公司)收到上海市藥品監督管理局簽發的《藥品生產現場檢查結果吿知書》。本次爲該等新建產線首次通過藥品生產質量管理規範符合性檢查(即GMP符合性檢查)。集團(即公司及控股子公司/單位,下同)針對本次檢查累計投入(含相關廠房設備等)約爲人民幣19,058萬元。
3月25日,瑞信:維持復星醫藥(02196)“跑贏大市”評級,目標價升至42港元。
最新的財務數據顯示,公司於2022年1季度,營業收入103.82億人民幣,淨利潤6.44億人民幣;營業收入同比增加28.87%,毛利潤同比增加8.37%,淨利潤同比減少34.17%。
盈立趨勢長盈模型最近一次交易信號,2022年5月10日出現觀望信號,觸發價格爲30.0港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.